普利製藥(300630.SZ):2022年度擬向銀行和金融機構申請不超30億元綜合授信額度
格隆匯1月11日丨普利製藥(300630.SZ)公佈,為滿足公司生產經營資金需要,進一步拓寬公司融資渠道,公司(含全資子公司及全資孫公司)2022年度擬向寧波銀行杭州分行、興業銀行杭州分行、招商銀行杭州分行、浙商銀行杭州分行、杭州銀行江城支行、工商銀行安慶龍嘯支行、浦發銀行杭州分行、中信銀行杭州臨平支行、交通銀行海南省分行、以及其他銀行和金融機構申請不超過人民幣30億元綜合授信額度,最終以各家銀行及金融機構實際審批的授信額度為準。
實際融資金額在總授信額度內,以銀行及金融機構與公司實際發生的融資金額為準,實際融資業務事項授權董事會的權限範圍審批。
同時公司提議授權董事長範敏華以及浙江瑞利藥業有限公司法人代表蒲建在各自的權限範圍內全權代表公司簽署上述授信額度內的一切與授信(包括但不限於辦理貸款、信用證、商業承兑匯票、國內保函及貿易融資等業務)有關的合同、協議、憑證等各項法律文件,由此產生的法律、經濟責任全部由公司或全資子公司,孫公司分別承擔。本次授權決議的有效期為一年,自股東大會審議通過之日起計算。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.